Albany Molecular Research (AMRI) Narrows Q3 Loss; Lowers FY11 Contract Revs Outlook
Tweet Send to a FriendGet Alerts AMRI Hot Sheet
Price: $10.91 --0%
EPS Growth %: +1,050.0%
Financial Fact:
Total revenue: 59.41M
Today's EPS Names:
REDF, REX, SNPS, More
EPS Growth %: +1,050.0%
Financial Fact:
Total revenue: 59.41M
Today's EPS Names:
REDF, REX, SNPS, More
Trade AMRI Now!
Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of ($0.19), versus ($0.33) reported last year. Revenue for the quarter came in at $50.23 million, versus $50.62 million reported last year.
Sees Q4 2011 contract revenue of $41-$45 million.
Sees FY2011 contract revenue of $171-$175 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Sees Q4 2011 contract revenue of $41-$45 million.
Sees FY2011 contract revenue of $171-$175 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
- Medtronic, Inc. (MDT) Tops Q4 EPS by 7c; Guides FY14
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
